Table 3.
Items | Treatments |
SEM | P-value | |||
---|---|---|---|---|---|---|
NCO | ANT | RLS1 | RLS2 | |||
IgA, (mg/L) | ||||||
28 d | 872.63c | 1,144.33c | 2,557.02b | 3,868.16a | 382.92 | <0.001 |
56 d | 602.36 | 948.40 | 898.81 | 775.87 | 62.59 | 0.211 |
IgM, (mg/L) | ||||||
28 d | 4.55c | 10.87b | 12.19b | 21.78a | 1.88 | <0.001 |
56 d | 26.70c | 43.98a | 32.53b | 32.84b | 2.00 | <0.001 |
IgY, (mg/L) | ||||||
28 d | 272.33c | 447.00b | 527.02a | 548.68a | 33.80 | <0.001 |
56 d | 573.71c | 824.23b | 1,014.12a | 930.50a,b | 52.10 | <0.001 |
a,b,cMean with different superscripts in the same row differ significantly (P < 0.05).
Abbreviations: ANT, basal diet supplemented with 30 mg/kg bacitracin; NCO, basal diet provided as control; RLS, rhamnolipid; RLS1, basal diet supplemented with 500 mg/kg RLS; RLS2, basal diet supplemented with 1,000 mg/kg RLS.